Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Inflammatory Bowel Diseases

  Free Subscription


Articles published in Dig Dis

Retrieve available abstracts of 98 articles:
HTML format



Single Articles


    February 2021
  1. SORRENTINO D, Nguyen VQ, Love K
    Fecal lactoferrin predicts primary non-response to biologic agents in inflammatory bowel disease.
    Dig Dis. 2021 Feb 25. pii: 000515432. doi: 10.1159/000515432.
    PubMed     Abstract available


  2. LEAL T, Goncalves M, Antunes P, Costa D, et al
    Sleep disturbance in Inflammatory Bowel Disease is associated with disease activity and adverse outcome.
    Dig Dis. 2021 Feb 15. pii: 000515218. doi: 10.1159/000515218.
    PubMed     Abstract available


    January 2021
  3. STREMMEL W, Vural H, Evliyaoglu O, Weiskirchen R, et al
    Delayed Release Phosphatidylcholine is Effective for Treatment of Ulcerative Colitis: A Meta-Analysis.
    Dig Dis. 2021 Jan 13. pii: 000514355. doi: 10.1159/000514355.
    PubMed     Abstract available


  4. MATEOS B, Saez-Gonzalez E, Moret I, Hervas D, et al
    Plasma Oncostatin M, TNF-alpha, IL-7, and IL-13 Network Predicts Crohn's Disease Response to Infliximab, as Assessed by Calprotectin Log Drop.
    Dig Dis. 2021;39:1-9.
    PubMed     Abstract available


  5. HUNT RH, East JE, Lanas A, Malfertheiner P, et al
    COVID-19 and Gastrointestinal Disease: Implications for the Gastroenterologist.
    Dig Dis. 2021;39:119-139.
    PubMed     Abstract available


  6. GRASS F, Zhu E, Brunel C, Hubner M, et al
    Crohn's versus Cancer: Comparison of Functional and Surgical Outcomes after Right-Sided Resections.
    Dig Dis. 2021;39:106-112.
    PubMed     Abstract available


  7. RUEDA GARCIA JL, Suarez-Ferrer C, Poza Cordon J, Martin-Arranz E, et al
    Doppler Activity and Ultrasonographic Detection of Intra-Abdominal Fistulas Are Predictors of Surgery in Crohn's Disease.
    Dig Dis. 2021;39:204-210.
    PubMed     Abstract available


  8. DE SOUSA MAGALHAES R, Xavier S, Curdia Goncalves T, Dias de Castro F, et al
    Does Perianal Disease Influence the Efficacy of Combination Therapy in Crohn's Disease?
    Dig Dis. 2021;39:417-428.
    PubMed     Abstract available


    November 2020
  9. YU T, Meng F, Xie M, Liu H, et al
    LncRNA PMS2L2 downregulates miR-24 through methylation to suppress cell apoptosis in ulcerative colitis.
    Dig Dis. 2020 Nov 25. pii: 000513330. doi: 10.1159/000513330.
    PubMed     Abstract available


    September 2020
  10. DRAGONI G, Innocenti T, Galli A
    Biomarkers of inflammation in Inflammatory Bowel Disease: how long before abandoning single-marker approaches?
    Dig Dis. 2020 Sep 17. pii: 000511641. doi: 10.1159/000511641.
    PubMed     Abstract available


    May 2020
  11. BARBERIO B, Zingone F, Frazzoni L, D''Inca R, et al
    REAL LIFE COMPARISON OF DIFFERENT ANTI-TNF BIOLOGIC THERAPIES FOR ULCERATIVE COLITIS TREATMENT: A RETROSPECTIVE COHORT STUDY.
    Dig Dis. 2020 May 25. pii: 000508865. doi: 10.1159/000508865.
    PubMed     Abstract available


    March 2020
  12. KANG MK, Kim KO, Kim MC, Park JG, et al
    Sarcopenia is a new risk factor of non-alcoholic fatty liver disease in patients with inflammatory bowel disease.
    Dig Dis. 2020 Mar 5. pii: 000506938. doi: 10.1159/000506938.
    PubMed     Abstract available


    February 2020
  13. HELWIG U, Braegger F, Kostev K, Schmidt C, et al
    Comparative Analysis of the 3-Year Persistence Rate with Second-Line Vedolizumab and Tumor Necrosis Factor-alpha Inhibitors in Patients with Inflammatory Bowel Disease Followed in Gastroenterology Practices in Germany.
    Dig Dis. 2020 Feb 11:1-8. doi: 10.1159/000506121.
    PubMed     Abstract available


    January 2020
  14. MIRIJELLO A, D'Errico MM, Curci S, Bossa F, et al
    Takotsubo Syndrome and Inflammatory Bowel Diseases: Does a Link Exist?
    Dig Dis. 2020;38:204-210.
    PubMed     Abstract available


  15. TANG Y, Zhao L, Lei N, Chen P, et al
    Crohn's Disease Patients with Depression Exhibit Alterations in Monocyte/Macrophage Phenotype and Increased Proinflammatory Cytokine Production.
    Dig Dis. 2020;38:211-221.
    PubMed     Abstract available


  16. REISCHL S, Troger J, Jesinghaus M, Kasajima A, et al
    Annexin A1 Expression Capacity as a Determinant for Disease Severity in Crohn's Disease.
    Dig Dis. 2020;38:398-407.
    PubMed     Abstract available


  17. KANI HT, Sakalli Kani A, Dural U, Basgoze E, et al
    The Effect of Dream Anxiety on Sleep Quality in Inflammatory Bowel Diseases.
    Dig Dis. 2020;38:380-389.
    PubMed     Abstract available


  18. LU R, Kassim T, Dave D, Klair JS, et al
    Diagnostic Yield of Colonoscopy in Young Adults with Lower Gastrointestinal Symptoms in a Multicenter Midwest Cohort.
    Dig Dis. 2020;38:484-489.
    PubMed     Abstract available


    November 2019
  19. MADIAS JE
    Inflammatory Bowel Disease and Takotsubo Syndrome: Cases of Horses or Zebras?
    Dig Dis. 2019 Nov 8:1. doi: 10.1159/000503252.
    PubMed    


    October 2019
  20. GAMBOA HE, Molle-Rios Z, Anupindi SA
    Underutilization of Bowel Ultrasound in North America in Children with Inflammatory Bowel Disease.
    Dig Dis. 2019 Oct 23:1-8. doi: 10.1159/000503920.
    PubMed     Abstract available


    May 2019
  21. COTTONE M, Sapienza C, Macaluso FS, Cannizzaro M, et al
    Psoriasis and Inflammatory Bowel Disease.
    Dig Dis. 2019 May 10:1-7. doi: 10.1159/000500116.
    PubMed     Abstract available


  22. CROOKS B, McLaughlin J, Limdi JK
    Diet and Inflammatory Bowel Disease: Thoughts on Food, Perceptions and Beliefs.
    Dig Dis. 2019 May 3:1-2. doi: 10.1159/000500083.
    PubMed    


    April 2019
  23. HINOJOSA J, Munoz F, Martinez-Romero GJ
    Relationship between Serum Adalimumab Levels and Clinical Outcome in the Treatment of Inflammatory Bowel Disease.
    Dig Dis. 2019 Apr 30:1-7. doi: 10.1159/000499870.
    PubMed     Abstract available


    February 2019
  24. EVEN DAR R, Mazor Y, Karban A, Ish-Shalom S, et al
    Risk Factors for Low Bone Density in Inflammatory Bowel Disease: Use of Glucocorticoids, Low Body Mass Index, and Smoking.
    Dig Dis. 2019 Feb 21:1-7. doi: 10.1159/000496935.
    PubMed     Abstract available


  25. DANESE S, Allez M, van Bodegraven AA, Dotan I, et al
    Unmet Medical Needs in Ulcerative Colitis: An Expert Group Consensus.
    Dig Dis. 2019 Feb 6:1-18. doi: 10.1159/000496739.
    PubMed     Abstract available


    January 2019
  26. SALES KMO, Cavalcanti RF, Nobre E Souza MA, Saraiva LGM, et al
    Gastroduodenal Symptoms in Inflammatory Bowel Disease Are Correlated with Gastric Emptying and Serum Levels of Active Ghrelin.
    Dig Dis. 2019 Jan 2:1-8. doi: 10.1159/000494920.
    PubMed     Abstract available


  27. BELTRAN B, Iborra M, Saez-Gonzalez E, Marques-Minana MR, et al
    Fecal Calprotectin Pretreatment and Induction Infliximab Levels for Prediction of Primary Nonresponse to Infliximab Therapy in Crohn's Disease.
    Dig Dis. 2019;37:108-115.
    PubMed     Abstract available


    November 2018
  28. ZIADE F, Rungoe C, Kallemose T, Paerregaard A, et al
    Biochemical Markers, Genotype, and Inflammation in Pediatric Inflammatory Bowel Disease: A Danish Population-Based Study.
    Dig Dis. 2018 Nov 13:1-7. doi: 10.1159/000494215.
    PubMed     Abstract available


  29. DE VRIES JHM, Dijkhuizen M, Tap P, Witteman BJM, et al
    Patient's Dietary Beliefs and Behaviours in Inflammatory Bowel Disease.
    Dig Dis. 2018 Nov 2:1-9. doi: 10.1159/000494022.
    PubMed     Abstract available


  30. CHETCUTI ZAMMIT S, Schembri J, Pisani A, Vella S, et al
    Vitamin D and Ulcerative Colitis: Is There a Relationship with Disease Extent?
    Dig Dis. 2018 Nov 1:1-6. doi: 10.1159/000494439.
    PubMed     Abstract available


    September 2018
  31. SUGIMOTO K, Ikeya K, Kato M, Matsuura A, et al
    Assessment of Long-Term Efficacy and Safety of Adalimumab in Patients with Ulcerative Colitis: Results from a 6-Year Real-World Clinical Practice.
    Dig Dis. 2018 Sep 11:1-10. doi: 10.1159/000493121.
    PubMed     Abstract available


    August 2018
  32. HOFFMANN P, Krisam J, Stremmel W, Gauss A, et al
    Real-World Outcomes of Vedolizumab Therapy in Ulcerative Colitis and Crohn's Disease at a Tertiary Referral Center.
    Dig Dis. 2018 Aug 22:1-12. doi: 10.1159/000492322.
    PubMed     Abstract available


  33. EBRAHIMI DARYANI N, Sadr M, Soltani S, Saghazadeh A, et al
    Association of T Helper 1 Cytokine Gene Single Nucleotide Polymorphisms with Ulcerative Colitis and Crohn's Disease.
    Dig Dis. 2018 Aug 22:1-12. doi: 10.1159/000492027.
    PubMed     Abstract available


    July 2018
  34. CAPANNOLO A, Ciccone F, Latella G
    Mastocytic Enterocolits and the Role of Mast Cells in Functional and Inflammatory Intestinal Disorders: A Systematic Review.
    Dig Dis. 2018 Jul 6:1-8. doi: 10.1159/000490490.
    PubMed     Abstract available


  35. PEYRIN-BIROULET L, Baumgart DC, Armuzzi A, Gionchetti P, et al
    Quality of Care in Ulcerative Colitis: A Modified Delphi Panel Approach.
    Dig Dis. 2018 Jul 3:1-8. doi: 10.1159/000489845.
    PubMed     Abstract available


    May 2018
  36. TESTA A, Imperatore N, Rispo A, Rea M, et al
    Beyond Irritable Bowel Syndrome: The Efficacy of the Low Fodmap Diet for Improving Symptoms in Inflammatory Bowel Diseases and Celiac Disease.
    Dig Dis. 2018 May 15:1-10. doi: 10.1159/000489487.
    PubMed     Abstract available


    January 2018
  37. OHEM J, Hradsky O, Zarubova K, Copova I, et al
    Evaluation of Infliximab Therapy in Children with Crohn's Disease Using Trough Levels Predictors.
    Dig Dis. 2018;36:40-48.
    PubMed     Abstract available


  38. MOSLI M, Sabbahi H, Alyousef H, Abdulhaq M, et al
    Risk Stratification of Patients with Crohn's Disease: A Retrospective Analysis of Clinical Decision Making and Its Impact on Long-Term Outcome.
    Dig Dis. 2018;36:49-55.
    PubMed     Abstract available


  39. CUOMO A, Sgambato D, D'Auria MV, Miranda A, et al
    Multi Matrix System Mesalazine Plus Rectal Mesalazine in the Treatment of Mild to Moderately Active Ulcerative Proctitis.
    Dig Dis. 2018;36:130-135.
    PubMed     Abstract available


  40. LATERZA L, Piscaglia AC, Minordi LM, Scoleri I, et al
    Multiparametric Evaluation Predicts Different Mid-Term Outcomes in Crohn's Disease.
    Dig Dis. 2018;36:184-193.
    PubMed     Abstract available


  41. YOUSUF H, Aleem U, Egan R, Maheshwari P, et al
    Elevated Faecal Calprotectin Levels are a Reliable Non-Invasive Screening Tool for Small Bowel Crohn's Disease in Patients Undergoing Capsule Endoscopy.
    Dig Dis. 2018;36:202-208.
    PubMed     Abstract available


  42. GIL-BORRAS R, Garcia-Ballesteros C, Benet-Campos C, Catalan-Serra I, et al
    B1a Lymphocytes (CD19+CD5+) Deficiency in Patients with Crohn's Disease and Its Relation with Disease Severity.
    Dig Dis. 2018;36:194-201.
    PubMed     Abstract available


  43. ITO Z, Uchiyama K, Odahara S, Takami S, et al
    Fatty Acids as Useful Serological Markers for Crohn's Disease.
    Dig Dis. 2018;36:209-217.
    PubMed     Abstract available


  44. PAUCHARD I, Nancey S, Hacard F, Williet N, et al
    Efficacy and Safety of Infliximab Tolerance Induction in Patients with Inflammatory Bowel Diseases who Experienced Acute Infusion Reactions.
    Dig Dis. 2018;36:417-426.
    PubMed     Abstract available


    December 2017
  45. GREUTER T, Vavricka SR, Biedermann L, Pilz J, et al
    Alicaforsen, an Antisense Inhibitor of Intercellular Adhesion Molecule-1, in the Treatment for Left-Sided Ulcerative Colitis and Ulcerative Proctitis.
    Dig Dis. 2017 Dec 5. pii: 000484979. doi: 10.1159/000484979.
    PubMed     Abstract available


    October 2017
  46. TAKEUCHI K, Shimoyama T, Yamamoto T
    Comparison of Safety and Efficacy of Tacrolimus versus Infliximab for Active Ulcerative Colitis.
    Dig Dis. 2017 Oct 19. doi: 10.1159/000481815.
    PubMed     Abstract available


    September 2017
  47. ASL BAAKHTARI S, McCombie A, Ten Bokkel Huinink S, Irving P, et al
    Observational Study of Perspectives of Inflammatory Bowel Disease Patients Concerning the Use of Corticosteroids.
    Dig Dis. 2017 Sep 2. doi: 10.1159/000478772.
    PubMed     Abstract available


    July 2017
  48. LOPETUSO LR, Petito V, Graziani C, Schiavoni E, et al
    Gut Microbiota in Health, Diverticular Disease, Irritable Bowel Syndrome, and Inflammatory Bowel Diseases: Time for Microbial Marker of Gastrointestinal Disorders?
    Dig Dis. 2017 Jul 7. doi: 10.1159/000477205.
    PubMed     Abstract available


    June 2017
  49. CAI JX, Barrow J, Parian A, Brant SR, et al
    Routine Pouchoscopy Prior to Ileostomy Takedown May Not Be Necessary in Patients with Chronic Ulcerative Colitis.
    Dig Dis. 2017 Jun 9. doi: 10.1159/000475808.
    PubMed     Abstract available


    April 2017
  50. PEZZILLI R, Pagano N
    Benign Exocrine Pancreatic Diseases in Inflammatory Bowel Diseases.
    Dig Dis. 2017 Apr 27. doi: 10.1159/000471481.
    PubMed     Abstract available


  51. MAHLICH J, Matsuoka K, Sruamsiri R
    Shared Decision Making and Treatment Satisfaction in Japanese Patients with Inflammatory Bowel Disease.
    Dig Dis. 2017 Apr 6. doi: 10.1159/000471795.
    PubMed     Abstract available


    March 2017
  52. ELIADOU E, Kini G, Huang J, Champion A, et al
    Intravenous Iron Replacement Improves Quality of Life in Hypoferritinemic Inflammatory Bowel Disease Patients with and without Anemia.
    Dig Dis. 2017 Mar 24. doi: 10.1159/000468145.
    PubMed     Abstract available


    January 2017
  53. PROTIC M, Markovic S, Tarabar D
    Case Report: Acute Flair of Ulcerative Colitis during Pregnancy Is Still a Major Problem.
    Dig Dis. 2017;35.
    PubMed     Abstract available


  54. REINISCH W
    Fecal Microbiota Transplantation in Inflammatory Bowel Disease.
    Dig Dis. 2017;35.
    PubMed     Abstract available


  55. BUER L, Hoivik ML, Medhus AW, Moum B, et al
    Does the Introduction of Biosimilars Change Our Understanding about Treatment Modalities for Inflammatory Bowel Disease?
    Dig Dis. 2017;35.
    PubMed     Abstract available


  56. COSNES J
    What Should Be Done in Inflammatory Bowel Disease Patients with Prior Malignancy?
    Dig Dis. 2017;35.
    PubMed     Abstract available


  57. DURICOVA D
    What Can We Learn from Epidemiological Studies in Inflammatory Bowel Disease?
    Dig Dis. 2017;35.
    PubMed     Abstract available


  58. BETTENWORTH D, Rieder F
    Pathogenesis of Intestinal Fibrosis in Inflammatory Bowel Disease and Perspectives for Therapeutic Implication.
    Dig Dis. 2017;35.
    PubMed     Abstract available


  59. DOROFEYEV AE, Rassokhina OA, Dorofeyeva AA
    Late-Onset of Acute Severe Ulcerative Colitis: Clinical Case.
    Dig Dis. 2017;35.
    PubMed     Abstract available


  60. KRUIS W, Nguyen PG, Morgenstern J
    Promises and Dangers of Combination Therapy.
    Dig Dis. 2017;35.
    PubMed     Abstract available


  61. GILS A
    Combining Therapeutic Drug Monitoring with Biosimilars, a Strategy to Improve the Efficacy of Biologicals for Treating Inflammatory Bowel Diseases at an Affordable Cost.
    Dig Dis. 2017;35.
    PubMed     Abstract available


  62. HIGGINS PD
    Measurement of Fibrosis in Crohn's Disease Strictures with Imaging and Blood Biomarkers to Inform Clinical Decisions.
    Dig Dis. 2017;35.
    PubMed     Abstract available


  63. STANGE EF
    Improvement of a 'Leaky' Intestinal Barrier.
    Dig Dis. 2017;35.
    PubMed     Abstract available


  64. ROGLER G, Biedermann L, Scharl M
    Anti-Cytokine Strategies beyond Anti-Tumour Necrosis Factor-alpha Therapy: Pathophysiology and Clinical Implications.
    Dig Dis. 2017;35.
    PubMed     Abstract available


  65. SANDS BE
    Leukocyte Anti-Trafficking Strategies: Current Status and Future Directions.
    Dig Dis. 2017;35.
    PubMed     Abstract available


  66. JAHNSEN J, Kaasen Jorgensen K
    Experience with Biosimilar Infliximab (Remsima(R)) in Norway.
    Dig Dis. 2017;35.
    PubMed     Abstract available


  67. DRASTICH P, Oliverius M
    Crohn's Disease and Intestinal Transplantation.
    Dig Dis. 2017;35.
    PubMed     Abstract available


  68. VEGH Z, Kurti Z, Lakatos PL
    Real-Life Efficacy, Immunogenicity and Safety of Biosimilar Infliximab.
    Dig Dis. 2017;35.
    PubMed     Abstract available


  69. FORBES GM
    Mesenchymal Stromal Cell Therapy in Crohn's Disease.
    Dig Dis. 2017;35.
    PubMed     Abstract available


  70. KVERKA M, Tlaskalova-Hogenova H
    Intestinal Microbiota: Facts and Fiction.
    Dig Dis. 2017;35.
    PubMed     Abstract available


  71. HAWKEY CJ
    Hematopoietic Stem Cell Transplantation in Crohn's Disease: State-of-the-Art Treatment.
    Dig Dis. 2017;35.
    PubMed     Abstract available


  72. KOLAR M, Duricova D, Bortlik M, Hruba V, et al
    Infliximab Biosimilar (Remsima) in Therapy of Inflammatory Bowel Diseases Patients: Experience from One Tertiary Inflammatory Bowel Diseases Centre.
    Dig Dis. 2017;35.
    PubMed     Abstract available


  73. VAVRICKA SR, Spasojevic M, Rogler G, Schoepfer AM, et al
    Long-Term Efficacy and Safety of Certolizumab Pegol in an Unselected Crohn's Disease Population: The FACTS III Survey.
    Dig Dis. 2017;35:423-432.
    PubMed     Abstract available


  74. ZHENG S, Wu C, Yang W, Xia X, et al
    An Analysis of Transcobalamin II Gene Polymorphisms and Serum Levels of Homocysteine, Folate and Vitamin B12 in Chinese Patients with Crohn's Disease.
    Dig Dis. 2017;35:463-471.
    PubMed     Abstract available


    January 2016
  75. MANTZARIS GJ
    Anti-TNFs: Originators and Biosimilars.
    Dig Dis. 2016;34.
    PubMed     Abstract available


  76. BERNSTEIN CN
    Psychological Stress and Depression: Risk Factors for IBD?
    Dig Dis. 2016;34.
    PubMed     Abstract available


  77. DANESE S, Fiocchi C
    Endothelial Cell-Immune Cell Interaction in IBD.
    Dig Dis. 2016;34.
    PubMed     Abstract available


  78. FEDORAK RN, Ismond KP
    Practical Considerations and the Intestinal Microbiome in Disease: Antibiotics for IBD Therapy.
    Dig Dis. 2016;34.
    PubMed     Abstract available


  79. LEONG RW, Mitrev N, Ko Y
    Hygiene Hypothesis: Is the Evidence the Same All Over the World?
    Dig Dis. 2016;34.
    PubMed     Abstract available


  80. KRUIS W, Phuong Nguyen G
    Iron Deficiency, Zinc, Magnesium, Vitamin Deficiencies in Crohn's Disease: Substitute or Not?
    Dig Dis. 2016;34.
    PubMed     Abstract available


  81. MAO R, Hu PJ
    The Future of IBD Therapy: Where Are We and Where Should We Go Next?
    Dig Dis. 2016;34.
    PubMed     Abstract available


  82. WRIGHT EK
    Calprotectin or Lactoferrin: Do They Help.
    Dig Dis. 2016;34.
    PubMed     Abstract available


  83. BLUMBERG RS
    Environment and Genes: What Is the Interaction?
    Dig Dis. 2016;34.
    PubMed     Abstract available


  84. YANG SK
    Personalizing IBD Therapy: The Asian Perspective.
    Dig Dis. 2016;34.
    PubMed     Abstract available


  85. CHO JH
    The Promise of Epigenetics. Has It Delivered New Insights?
    Dig Dis. 2016;34.
    PubMed     Abstract available


  86. IACUCCI M, Ghosh S
    Mucosal Healing - How Deep Is Enough?
    Dig Dis. 2016;34.
    PubMed     Abstract available


  87. GEARRY RB
    IBD and Environment: Are There Differences between East and West.
    Dig Dis. 2016;34.
    PubMed     Abstract available


  88. VAVRICKA SR, Rogler G, Biedermann L
    High Altitude Journeys, Flights and Hypoxia: Any Role for Disease Flares in IBD Patients?
    Dig Dis. 2016;34.
    PubMed     Abstract available


  89. KURTI Z, Vegh Z, Golovics PA, Lakatos PL, et al
    'Treat to Target' - Lessons Learnt.
    Dig Dis. 2016;34.
    PubMed     Abstract available


  90. ROGLER G
    Preface.
    Dig Dis. 2016;34.
    PubMed    


  91. COSNES J
    Smoking and Diet: Impact on Disease Course?
    Dig Dis. 2016;34.
    PubMed     Abstract available


  92. HERFARTH HH
    Methotrexate for Inflammatory Bowel Diseases - New Developments.
    Dig Dis. 2016;34.
    PubMed     Abstract available


  93. KUMP P, Hogenauer C
    Any Future for Fecal Microbiota Transplantation as Treatment Strategy for Inflammatory Bowel Diseases?
    Dig Dis. 2016;34 Suppl 1:74-81.
    PubMed     Abstract available


  94. KHANNA R, Feagan BG
    Emerging Therapies for Inflammatory Bowel Diseases.
    Dig Dis. 2016;34 Suppl 1:67-73.
    PubMed     Abstract available


  95. LISSNER D, Siegmund B
    Are Immunosuppressants Becoming Obsolete?
    Dig Dis. 2016;34 Suppl 1:56-60.
    PubMed     Abstract available


  96. HILDNER K, Punkenburg E, Abendroth B, Neurath MF, et al
    Immunopathogenesis of IBD: Batf as a Key Driver of Disease Activity.
    Dig Dis. 2016;34 Suppl 1:40-7.
    PubMed     Abstract available


  97. ATREYA R, Neurath MF
    Predicting Therapeutic Response by in vivo Molecular Imaging in Inflammatory Bowel Diseases.
    Dig Dis. 2016;34:552-7.
    PubMed     Abstract available


  98. XAVIER RJ
    Microbiota as Therapeutic Targets.
    Dig Dis. 2016;34:558-65.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Inflammatory Bowel Diseases is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: